{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:27:55Z","timestamp":1792682875709,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014064","name":"Universidad de Salamanca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03409-y","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:20Z","timestamp":1764311360000},"page":"333-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Efficacy of Talquetamab vs. Real-World Physician\u2019s Choice of Treatment in Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion\/MoMMent"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct3399799","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04634552","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04035226","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05160584","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hermann","family":"Einsele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Anguille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ghilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksiy","family":"Orel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenny","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo F.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"5","key":"3409_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol"},{"key":"3409_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"issue":"S1","key":"3409_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.5045\/br.2020.S008","volume":"55","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55(S1):S43\u201353. https:\/\/doi.org\/10.5045\/br.2020.S008.","journal-title":"Blood Res"},{"issue":"1","key":"3409_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"3409_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3409_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66\u201376. https:\/\/doi.org\/10.1111\/bjh.14193.","journal-title":"Br J Haematol"},{"key":"3409_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100808","volume":"49","author":"K Ramasamy","year":"2021","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49:100808.","journal-title":"Blood Rev"},{"issue":"9","key":"3409_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"5","key":"3409_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. Locommotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"issue":"9","key":"3409_CR10","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase\u00a02 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"issue":"6","key":"3409_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"issue":"8","key":"3409_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"3409_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"issue":"10301","key":"3409_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase\u00a01 study. Lancet. 2021;398(10301):665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(21)01338-6.","journal-title":"Lancet"},{"key":"3409_CR15","unstructured":"TALVEY (talquetamab-tgvs). Prescribing information. Horsham, PA: Janssen Biotech, Inc."},{"key":"3409_CR16","unstructured":"European Medicines Agency: TALVEY\u2122 (talquetamab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/talvey. Accessed Apr 14, 2025."},{"issue":"24","key":"3409_CR17","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"3409_CR18","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase\u00a01\u20132 study. Lancet Haematol. 2025;12(4):e269\u201381. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5.","journal-title":"Lancet Haematol"},{"issue":"12","key":"3409_CR19","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486\u201394.","journal-title":"Am J Hematol"},{"issue":"5","key":"3409_CR20","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412\u201325.","journal-title":"Adv Ther"},{"key":"3409_CR21","unstructured":"ClinicalTrials.gov: a study of real-life current standards of care in participants with relapsed and\/or refractory multiple myeloma (MoMMent). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05160584. Accessed June 18, 2025."},{"issue":"4","key":"3409_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1007\/s12325-024-02797-x","volume":"41","author":"H Einsele","year":"2024","unstructured":"Einsele H, Moreau P, Bahlis N, et al. Comparative efficacy of talquetamab vs. current treatments in the LocoMMotion and MoMMent studies in patients with triple-class-exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41(4):1576\u201393. https:\/\/doi.org\/10.1007\/s12325-024-02797-x.","journal-title":"Adv Ther"},{"key":"3409_CR23","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/S2152-2650(24)01953-0","volume":"24","author":"M-V Mateos Manteca","year":"2024","unstructured":"Mateos Manteca M-V, Jakubowiak A, Einsele H, et al. Talquetamab vs real-world physician\u2019s choice in patients with relapsed\/refractory multiple myeloma and prior B-cell maturation antigen therapy: analyses of MonumenTAL-1 vs LocoMMotion\/MoMMent. Clin Lymphoma Myeloma Leuk. 2024;24:S69\u201370. https:\/\/doi.org\/10.1016\/S2152-2650(24)01953-0.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"3409_CR24","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"521","key":"3409_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390\u2013400.","journal-title":"J Am Stat Assoc"},{"issue":"23","key":"3409_CR26","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129(23):3746\u201360. https:\/\/doi.org\/10.1002\/cncr.34987.","journal-title":"Cancer"},{"issue":"1","key":"3409_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfab158.","journal-title":"Clin Kidney J"},{"issue":"1","key":"3409_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12874-020-00947-7","volume":"20","author":"H Raad","year":"2020","unstructured":"Raad H, Cornelius V, Chan S, Williamson E, Cro S. An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome. BMC Med Res Methodol. 2020;20(1):70. https:\/\/doi.org\/10.1186\/s12874-020-00947-7.","journal-title":"BMC Med Res Methodol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03409-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:31:55Z","timestamp":1769765515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03409-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3409"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03409-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hermann Einsele has received honoraria from Amgen, BMS, EUSA Pharma, Genesis, GSK, Johnson & Johnson, Novartis, Sanofi, and Takeda, travel expenses from Amgen, EUSA Pharma, and Takeda and research funding from Amgen, Genesis, GSK, Johnson & Johnson, Sanofi, and Takeda. Philippe Moreau has served in a consulting or advisory role and received honoraria from AbbVie, Amgen, Celgene, Celgene, GSK, Johnson & Johnson, Oncopeptides, and Sanofi. Nizar Bahlis has a consulting or advisory role with AbbVie, Amgen, BMS, Forus, GSK, Johnson & Johnson, Pfizer, Sanofi, and Takeda, received honoraria from AbbVie, Amgen, BMS, Forus, Johnson & Johnson, and Sanofi, been a member of the steering committee at AbbVie, GSK, and Johnson & Johnson and has received research funding from Johnson & Johnson and Pfizer. Manisha Bhutani has received research support (paid to institution) from Johnson & Johnson, Amgen, BMS\/Celgene, AbbVie, Takeda, Caribou Biosciences, and The Binding Site, and serves on the advisory board for Caribou Biosciences. Laure Vincent has received funding from Johnson & Johnson, honoraria from BMS and Johnson & Johnson, travel expenses from Amgen, BMS, GSK, Johnson & Johnson, Sanofi, and Takeda, and has participated on an advisory board for BMS, Johnson & Johnson, and Takeda. Lionel Karlin has served in a consulting or advisory role and received honoraria from Amgen, BMS\/Celgene, GSK, Johnson & Johnson, Sanofi, Stemline, and Takeda, has received travel expenses from Amgen, BMS\/Celgene, Johnson & Johnson, Sanofi, and Takeda, and has an immediate family member employed by Laoratoira Aguettant. Aurore Perrot has received honoraria or served a consulting role with AbbVie, Amgen, BMS, Johnson & Johnson, Pfizer, Sanofi, and Takeda. Hartmut Goldschmidt has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, Johnson & Johnson, Sanofi, and Takeda, received travel funding from Johnson & Johnson and Sanofi, honoraria from Amgen, BMS, Celgene, Chugai Pharma, GSK, Johnson & Johnson, Novartis, and Sanofi, research funding from Amgen, BMS, Celegen, Chugai Pharma Europe, Incyte, Johnson & Johnson, Molecular Partners, MSD, Mundipharma, Novartis, and Takeda, and discloses other relationships with Amgen, Celgene\/BMS, Chugai Pharma Europe, Johnson & Johnson, and Sanofi. Niels W. C. J. van de Donk has received research support (paid to institution) from Johnson & Johnson, Amgen, Celgene, Novartis, Cellectis, and BMS, and serves on advisory boards for Johnson & Johnson, Amgen, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Merck, Kite Pharma, Pfizer, AbbVie, and Servier. Enrique M. Ocio has received honoraria from AbbVie, Amgen, BMS, GSK, Johnson & Johnson, Menarini, Oncopeptides, Pfizer, Regeneron and Takeda, reports a consulting or advisory role with Amgen, AbbVie, BMS, GSK, Johnson & Johnson, Menarini, Oncopeptides, Pfizer, Sano and Takeda and is on the speakers\u2019 bureau for Johnson & Johnson. Joaqu\u00edn Mart\u00ednez L\u00f3pez reports a consulting or advisory role with Celgene and Johnson & Johnson and is on the speakers\u2019 bureau for BMS, Celgene, Johnson & Johnson and Novartis. Paula Rodr\u00edguez-Otero reports a consulting or advisory role with AbbVie, BMS, GSK, Johnson & Johnson, Pfizer, and Sanofi, is on the speakers\u2019 bureau for BMS, GSK, Johnson & Johnson, and Sanofi; has received travel, accommodations, and expenses from Pfizer, and has received honoraria from AbbVie, Celgene, GSK, H3 Biomedicine, Johnson & Johnson, Pfizer, and Sanofi. Dominik Dytfeld has received honoraria from Amgen and BMS and is a member of an entity\u2019s Board of Directors or advisory committees for Amgen and BMS. Andrzej Jakubowiak has received honoraria from and reports a consulting\/advisory role for AbbVie, Amgen, BMS, GSK, Johnson & Johnson, and Sanofi. Carolina Schinke has received honoraria from Johnson & Johnson and Pfizer and has participated in advisory board meetings for Arxellx, Johnson & Johnson, and Pfizer. Britta Besemer has received honoraria from Amgen, GSK, Johnson & Johnson and Sanofi and has received travel accommodations and\/or expenses from Amgen and Johnson & Johnson. S\u00e9bastien Anguille has no conflicts to disclose. Salomon Manier reports a consulting or advisory role with AbbVie, Adaptive Biotechnology, Amgen, BMS\/Celgene, GSK, Johnson & Johnson, Novartis, Regeneron, Roche, Sanofi, and Takeda. Leo Rasche has received honoraria from BMS, GSK, Johnson & Johnson, Pfizer, Roche, and Sanofi, is a member of a board of directors or advisory committee for Amgen, BMS, Johnson & Johnson, Pfizer, and Sanofi, reports a consulting or advisory role with Amgen, BMS, GSK, Johnson & Johnson, Pfizer, and Sanofi; and has received research funding from BMS and Skyline Dx. Raphael Teipel has received honoraria from AbbVie, Amgen, BMS, Gilead, GSK, Johnson & Johnson, Oncopeptides, Sanofi, Stemline, and Takeda, reports a consulting or advisory role with Amgen, BMS, and Johnson & Johnson, and research funding from Johnson & Johnson. Christof Scheid has received honoraria from Amgen, BMS\/Celgene, GSK, Johnson & Johnson, Novartis, Pfizer, Sanofi\/Aventis and Takeda, reports a consulting or advisory role with Amgen, BMS\/Celgene, GSK, Johnson & Johnson, Roche, and Sanofi\/Aventis, has received research funding from Johnson & Johnson, Novartis, and Takeda, and has received travel accommodations and\/or expenses from Amgen, BMS\/Celgene, and Johnson & Johnson. Charlotte Pawlyn has received honoraria from BMS\/Celgene, Johnson & Johnson, and Sanofi and reports a consulting or advisory role with AbbVie, BMS\/Celgene, Johnson & Johnson, and Sanofi. Michele Cavo has received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Johnson & Johnson, Takeda, is a member of a board of directors or advisory committee for AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Johnson & Johnson, Takeda, has received research funding from Johnson & Johnson and Celgene, and is on the speakers\u2019 bureau for Celgene and Johnson & Johnson. Joris Diels, Francesca Ghilotti, Bonnie W. Lau, Thomas Renaud, Oleksiy Orel, Fenny Ong, Diogo F. Ramos, Eric Ammann, Trilok Parekh, and Claire Albrecht are employees of Johnson & Johnson and may own stock in Johnson & Johnson. Katja Weisel has served in a consulting or advisory role for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Johnson & Johnson, Karyopharm Therapeutics, Oncopeptides, Roche, Sanofi, and Takeda, received travel, accommodations, and\/or expenses from Amgen, BMS, Celgene, GSK, Johnson & Johnson, and Takeda, honoraria from AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Johnson & Johnson, Karyopharm Therapeutics, Novartis, Oncopeptides, Pfizer, Roche\/Genentech, Sanofi, and Takeda, and research funding from Amgen, BMS, Celgene, GSK, Johnson & Johnson, and Sanofi. Mar\u00eda-Victoria Mateos has served in a consulting or advisory role for AbbVie, Amgen, Celgene, GSK, Johnson & Johnson, Pfizer, Regeneron, Roche\/Genentech, and Takeda, and received honoraria from AbbVie\/Genentech, Amgen, Celgene, GSK, Johnson & Johnson, Sanofi, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"MonumenTAL-1 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. An independent ethics committee or institutional review board at each study center approved the study protocol (Table\u00a0\n                      \n                      ). The LocoMMotion and MoMMent studies were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. An independent ethics committee\/institutional review board at each center approved the study protocol (Tables\u00a0\n                      \n                      ,\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}